Preclinical trial on the use of doxycycline for the treatment of adenocarcinoma of the duodenum

Galván‑Salazar,Hector R.; Soriano‑Hernández,Alejandro D.; Montes‑Galindo,Daniel A.; Ceja Espíritu,Gabriel; Guzman‑Esquivel,José; Rodríguez‑Sánchez,Iram P.; Newton‑Sánchez,Oscar A.; Martinez‑Fierro,Margarita L.; Briseño Gómez,Xóchitl G.; Rojas‑Martínez,Augusto; Delgado‑Enciso,Iván

doi:10.3892/mco.2016.1013

Preclinical trial on the use of doxycycline for the treatment of adenocarcinoma of the duodenum

Authors:
- Hector R. Galván‑Salazar
- Alejandro D. Soriano‑Hernández
- Daniel A. Montes‑Galindo
- Gabriel Ceja Espíritu
- José Guzman‑Esquivel
- Iram P. Rodríguez‑Sánchez
- Oscar A. Newton‑Sánchez
- Margarita L. Martinez‑Fierro
- Xóchitl G. Briseño Gómez
- Augusto Rojas‑Martínez
- Iván Delgado‑Enciso
View Affiliations

Affiliations: School of Medicine, University of Colima, Colima 28040, Mexico, State Cancer Institute, State Ministry of Health of Colima, Colima 28000, Mexico, Zone No. 1 General Hospital General of the Mexican Social Security Institute (IMSS), Colima 28000, Mexico, Department of Genetics, School of Medicine, Autonomous University of Nuevo León (UANL), Monterrey, Nuevo León 64460, Mexico, Molecular Medicine Laboratory, Academic Unit of Human Medicine and Health Sciences, Autonomous University of Zacatecas, Zacatecas 98160, Mexico, Center of Research and Development in Health Sciences and School of Medicine, UANL, Monterrey, Nuevo León 64460, Mexico
Published online on: September 8, 2016 https://doi.org/10.3892/mco.2016.1013
Pages: 657-659

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Adenocarcinoma of the duodenum comprises 50‑70% of duodenal tumors. There is an increase in extracellular matrix metalloproteinases in this disease and it has been suggested that they play an important role in the development and pathology. Therefore, new therapeutic recommendations based on inhibitors of these enzymes, such as doxycycline, are under investigation. The cytotoxic effect of doxycycline was evaluated in the HuTu‑80 duodenal adenocarcinoma cell line and its antitumor effect was determined in an immunodeficient murine model. A 10‑µM (4.4 µg̸ml) concentration of doxycycline was capable of causing apoptosis in 90% of the culture cells. doxycycline was also responsible for a decrease in tumor growth and an increase in the survival of the mice with HuTu‑80‑cell tumors. These results suggest that doxycycline is a potential cytotoxic and antitumor agent effective in the treatment of adenocarcinoma of the duodenum.

View Figures

View References

1	Bakaeen F, Murr MM, Sarr MG, Thompson GB, Farnell MB, Nagorney DM, Farley DR, van Heerden JA, Wiersema LM, Schleck CD and Donohue JH: What prognostic factors are important in duodenal adenocarcinoma? Arch Surg. 135:635–641; discussion 641–642. 2000. View Article : Google Scholar : PubMed/NCBI
2	Tocchi A, Mazzoni G, Puma F, Miccini M, Cassini D, Bettelli E and Tagliacozzo S: Adenocarcinoma of the third and fourth portions of the duodenum: Results of surgical treatment. Arch Surg. 138:80–85. 2003. View Article : Google Scholar : PubMed/NCBI
3	Hidalgo M and Eckhardt SG: Development of matrix metalloproteinase inhibitors in cancer therapy. J Natl Cancer Inst. 93:178–193. 2001. View Article : Google Scholar : PubMed/NCBI
4	Gu Y, Lee HM, Sorsa T, Salminen A, Ryan ME, Slepian MJ and Golub LM: Non-antibacterial tetracyclines modulate mediators of periodontitis and atherosclerotic cardiovascular disease: A mechanistic link between local and systemic inflammation. Pharmacol Res. 64:573–579. 2011. View Article : Google Scholar : PubMed/NCBI
5	Leite LM, Carvalho AG, Ferreira PL, Pessoa IX, Gonçalves DO, Ade A Lopes, Góes JG, Alves VC, Leal LK, Brito GA and Viana GS: Anti-inflammatory properties of doxycycline and minocycline in experimental models: An in vivo and in vitro comparative study. Inflammopharmacology. 19:99–110. 2011. View Article : Google Scholar : PubMed/NCBI
6	Jantzie LL and Todd KG: Doxycycline inhibits proinflammatory cytokines but not acute cerebral cytogenesis after hypoxia-ischemia in neonatal rats. J Psychiatry Neurosci. 35:20–32. 2010. View Article : Google Scholar : PubMed/NCBI
7	Osten L, Kubitza M, Gallagher AR, Kastner J, Olbrich H, de Vries U, Kees F, Lelongt B, Somlo S, Omran H and Witzgall R: Doxycycline accelerates renal cyst growth and fibrosis in the pcy/pcy mouse model of type 3 nephronophthisis, a form of recessive polycystic kidney disease. Histochem Cell Biol. 132:199–210. 2009. View Article : Google Scholar : PubMed/NCBI
8	Soriano-Hernández AD, Galvan-Salazar HR, Montes-Galindo DA, Rodriguez-Hernandez A, Martinez-Martinez R, Guzman-Esquivel J, Valdez-Velazquez LL, Baltazar-Rodriguez LM, Espinoza-Gómez F, Rojas-Martinez A, et al: Antitumor effect of meclofenamic acid on human androgen-independent prostate cancer: A preclinical evaluation. Int Urol Nephrol. 44:471–477. 2012. View Article : Google Scholar : PubMed/NCBI
9	Sagar J, Sales K, Dijk S, Taanman J, Seifalian A and Winslet M: Does doxycycline work in synergy with cisplatin and oxaliplatin in colorectal cancer? World J Surg Oncol. 7:22009. View Article : Google Scholar : PubMed/NCBI
10	Onoda T, Ono T, Dhar DK, Yamanoi A, Fujii T and Nagasue N: Doxycycline inhibits cell proliferation and invasive potential: Combination therapy with cyclooxygenase-2 inhibitor in human colorectal cancer cells. J Lab Clin Med. 143:207–216. 2004. View Article : Google Scholar : PubMed/NCBI
11	Onoda T, Ono T, Dhar Dk, Yamanoi A and Nagasue N: Tetracycline analogues (doxycycline and COL-3) induce caspase-dependent and -independent apoptosis in human colon cancer cells. Int J Cancer. 118:1309–1315. 2006. View Article : Google Scholar : PubMed/NCBI
12	Lokeshwar BL, Selzer MG, Zhu BQ, Block NL and Golub LM: Inhibition of cell proliferation, invasion, tumor growth and metastasis by an oral non-antimicrobial tetracycline analog (COL-3) in a metastatic prostate cancer model. Int J Cancer. 98:297–309. 2002. View Article : Google Scholar : PubMed/NCBI
13	Wang A, Siegel E, Mayes DA, Hutchins LF and Yi Z: Anti-tumor effect of doxycycline on glioblastoma cells. Journal of Cancer Molecules. 3:147–153. 2007.
14	Fife RS, Sledge GW Jr, Roth BJ and Proctor C: Effects of doxycycline on human prostate cancer cells in vitro. Cancer Lett. 127:37–41. 1998. View Article : Google Scholar : PubMed/NCBI
15	Fife RS and Sledge GW Jr: Effects of doxycycline on in vitro growth, migration, and gelatinase activity of breast carcinoma cells. Lab Clin Med. 125:407–411. 1995.
16	Fife RS, Rougraff TT, Proctor C and Sledge GW Jr: Inhibition of proliferation and induction of apoptosis by doxycycline in cultured human osteosarcoma cells. J Lab Clin Med. 130:530–534. 1997. View Article : Google Scholar : PubMed/NCBI
17	Bitik B, Kalpakci Y, Altan E, Dogan E and Altundag K: Successful treatment of primary duodenal carcinoma with bilateral adrenal metastases with docetaxel-cisplatin-5-fluorouracil regimen. Ann Oncol. 20:394–395. 2009. View Article : Google Scholar : PubMed/NCBI